ArticleMalaria journal2025
Determination of the residual efficacy of broflanilide (VECTRON™ T500) insecticide for indoor residual spraying in a semi-field setting in Ethiopia.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Determination of the preliminary discriminating concentration of broflanilide against malaria vector mosquito Anopheles gambiae by multi-centre susceptibility testing.Malaria journal · 2026Article
- Susceptibility of the invasive malaria vector Anopheles stephensi in Ethiopia to novel chemical insecticides and insect growth regulator.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rotational use of insecticides with diverse modes of action in indoor residual spraying (IRS) is pivotal for enhancing malaria vector control and addressing insecticide resistance. A key factor in national malaria vector control/elimination programmes is the rate at which these insecticides decay. VECTRON™ T500, with broflanilide as its active ingredient, is a recently developed candidate insecticide formulation which has shown promising results in certain phase II experimental hut trials. However, its residual efficacy across different settings has not been thoroughly investigated. This study evaluated the efficacy of VECTRON™ T500 on various wall surfaces (mud, dung, paint, and cement) and assessed its decay rates over time in Ethiopia.
methodsInsectary-reared Anopheles arabiensis Sekoru strain mosquitoes were used to evaluate the residual efficacy of VECTRON™ T500. Female mosquitoes, aged three to five days were used for the bioassays. Seven 'tukul' type test huts, each hut with a distinct wall type (mud, dung, painted, and cemented) were used for the study. Three huts received VECTRON™ T500; three huts were sprayed with Actellic 300CS, and one hut served as a negative control (sprayed with water only).
resultsVECTRON™ T500 induced over 80% mortality across all wall surface types throughout the entire nine-month study period. In contrast, Actellic
conclusionOverall, the mortality rates achieved with VECTRON™ T500 extended up to nine months across all treated wall surface types, outperforming Actellic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.